Reyvow (lasmiditan) is an FDA-approved treatment from Lilly for the acute treatment of migraine with or without aura in adults. FDA has not approved it as a preventive treatment of migraine.
In October, Lilly announced that the drug showed superior pain freedom after two hours of ingestion in two-thirds of migraine attacks in a Phase 3 study.
FDA approved the drug in October 2019. The drug became commercially available a few months later in February 2020.
Filed Under: clinical trials, Neurological Disease